Company Symposia

Forum Auditorium

Monday, 2 July 2018

11:45 – 13:00 Company Symposium Merck

“How to improve ART efficiency and risk management to shorten time to live birth”

Chair: Ernesto Bosch, Valenica Spain

 11:45 - 11:50   Welcome│Thomas D’Hooghe (Darmstadt, Germany) 
 11:50 - 11:55
 Delphi consensus paper on how specific treatment approaches can shorten TTLB│Ernesto Bosch (Valencia, Spain)
 11:55 - 12:15  
 Optimize oocytes yield to maximize live births│Sandro Esteves (Sao Paulo, Brazil)
 12:15 - 12:35 
 Remove risks in ART without compromising other outcomes such as live birth rate│Zi-Jiang Chen (Shandong, China)
 12:35 - 12:55   
 Embrace Fertility Technologies to expand ART knowledge and patient’s opportunities│Marcos Meseguer (Valencia, Spain)
 12:55 - 13:00  
 Summary and Closing remarks│Ernesto Bosch (Valencia, Spain)

14:00 – 15:15
Company Symposium Cooper Surgical Download announcement here

Advancing Technologies For Reproductive Genetics: Where Are We Heading?
Chair: Tony Gordon, CooperGenomics

  • Where Are We Now: The Challenges and Benefits of Genetics in IVF | Tony Gordon (VP Business Development, CooperGenomics)
  • Next Steps in Preimplantation Genetic Testing | Santiago Munné (Co-Founder, CooperGenomics)
  • CRISPR-Cas9 in Assisted Reproduction: The Science and the Ethical Challenges | Mark Hughes (Co-Founder and Chief Medical Officer, CooperGenomics)


17:00 – 18:15 Company Symposium Gedeon Richter - Download announcement here

“The future of cryopreservation in ART”

Chairs: Professor Dr Ariane Germeyer MD, PhD – Germany & Professor Dr Nikolaos Polyzos MD, PhD – Spain

  • Freeze-all in ART: a shift in practice or still a walk on thin ice?│Professor Dr Michel De Vos MD, PhD – Belgium
  • Can we optimise the reproductive outcomes of fresh and frozen embryo transfer?│Professor Dr Peter Humaidan MD, DMSc – Denmark
  • How to optimise the ‘freeze-all’ procedure: for whom, when and how?│Dr Ernesto Bosch MD, PhD – Spain

Tuesday, 3 July 2018 

11:45 – 13:00 Company Symposium Ferring - Download announcement here

The evolution of ART: A modern approach to ovarian stimulation

11:45 – 11:50     Evolution of gonadotrophin preparations for ovarian stimulation│Bart Fauser        

11:50 – 12:10     AMH: The backbone to personalising ovarian stimulation│Elena Labarta

12:10 – 12:30     New insights on HP-hMG – MEGASET HR│Michael Alper        

12:30 – 12:50     Follitropin delta: Ovarian stimulation with efficacy and safety at its core Jon Havelock              

12:50 – 13:00     Conclusions│Bart Fauser


14:00 – 15:15 Company Symposium IBSA – Download announcement here

“A genic path for ART going forward”

Chairmen: Dominique de Ziegler (France) – Claus Yding Andersen (Denmark)

14.00                 Welcome and introduction

14.05-14.25       Selecting one embryo for transfer: genetics at its best│Richard Scott (USA)

14.25-14.45       The pros and cons of gene editing in the human germline│Björn Heindryckx (Belgium)

14.45-15.05       Mitochondrial determinants of embryo quality│Francesco Fiorentino (Italy)

15.05-15.15       Discussion and conclusion

15.15                  End of session


17:00 – 18:15 Company Symposium MSD - Download announcement here

Optimal Recruitment and Receptivity: Are They Mutually Exclusive?

Chair: Pedro N. Barri (Spain)

17:00 – 17:05     Welcome and Introduction│Pedro N. Barri  

17:05 – 17:25     Are We in Control of Controlled Ovarian Stimulation?│Juan Antonio García Velasco

17:25 – 17:45     New Insights in Follicular Recruitment│Christophe Blockeel

17:45 – 18:05    How to Achieve a Receptive Endometrium for Fresh Embryo Transfer│Human M. Fatemi       

18:05 – 18:15    Closing Remarks│Pedro N. Barri 


Wednesday, 4 July 2018 

08:30 – 09:45 Company Symposium Abbott Products Operations

“Dydrogesterone: Shining New Light on Life”

Chairmen – Herman Tournaye & Georg Griesinger

08:30          Opening│H. Tournaye

08:40          Do Progestogens Fit in the ESHRE Guidelines for Treatment of Recurrent Miscarriage│Prof. Carp

09:00          Luteal Support in ART: Could Dydrogesterone Become the New Gold Standard?│Prof. Blockeel

09:20          Immunomodulation in Early Pregnancy│Prof. Arck

09:40          Ending│G. Griesinger

09:45          Close


12:00 – 13:15 Company Symposium Japan A-PART & Vitrolife - Download announcement here

“How time-lapse technology can improve clinical outcome in natural and mild stimulation cycles”

Chairmen: Dr Hiroaki Yoshida (president of Japan A-PART, Sendai ART Clinic, Japan & Dr Markus Montag, ilabcomm, Germany

  • Introduction to A-PART and IVF market in Japan│Dr Hiroaki Yoshida (Sendai ART Clinic, Japan)
  • The role of time-lapse technology in mild/low stimulation program│Dr Keiichi Kato (Kato Ladies Clinic, Japan)
  • The development and application of algorithms specific to mild/low stimulation│Dr Markus Montag (ilabcomm, Germany)
  • The big picture: how traditional grading, PGS and time-lapse complement each other│Dr Cristina Hickman (British Fertility Society & Imperial College London, UK)